secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2024-06-10T23:59:59+00:00
Accession:  0001213900-24-051210
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics stockholders approve all five proposals at 2024 Annual Meeting
--------------------------------------------------------------------------------

- Class I directors elected: Jane Huang (9.66M for), Richard Levy (9.64M for), Michael Solomon (9.56M for); broker non-votes 3.81M.
- Ratification of Ernst & Young as auditor: 13.40M for, 189,574 against, 1,424 abstentions.
- Advisory vote on exec compensation approved: 7.00M for, 196,457 against, 2.59M abstentions plus broker non-votes.
- 2024 Equity Incentive Plan and 2024 Employee Stock Purchase Plan both approved: 9.60M and 9.65M for, respectively.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024051210/0001213900-24-051210-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390024051210/ea0207579-8k_protara.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-051210

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer